Preclinical studies suggest statins may help prevent prostate cancer (PC), but epidemiologic results are mixed. Many epidemiological studies have relatively short prediagnosis drug exposure data, which may miss some statin use. We completed a nested case-control study investigating the impact of statin use on PC diagnosis and clinically significant PC using data from men aged 40 years in the Canadian province of Saskatchewan between 1990 and 2010. Drug exposure histories were derived from a population-based prescription drug database. We used conditional logistic regression to model use of statins as a class and stratified analyses for groups defined by lipophilicity. Clinically significant PC was defined as Gleason score 8-10 OR stage C or D or III or IV at diagnosis. 12,745 cases of PC were risk-set matched on age and geographic location to 50,979 controls. Greater than 90% of subjects had prediagnosis drug exposure histories >15 years. 2,064 (16.2%) cases and 7,956 (15.6%) controls were dispensed one or more statin prescriptions. In multivariable models, ever prescription of statins was not associated with PC diagnosis (OR 0.97; 95% CI 0.90-1.05). Neither lipophilic statins (OR 0.96, 95% CI 0.88-1.04) nor hydrophilic statins (OR 1.06, 95% CI 0.95-1.20) impacted PC diagnosis. There was no effect of the dose or duration of statin use. Diagnosis of clinically significant PC decreased with statin use (OR 0.84, 95% CI 0.73-0.97). Statin use is not associated with overall PC risk, regardless of duration or dose of statin exposure. Statin use is associated with a decreased risk of clinically significant PC.
Prostate cancer (PC) is the most common noncutaneous malignancy diagnosed among men and the third leading cause of cancer-related deaths in North America. 1 Despite being such a common disease, little is known about the causes of PC. Only three risk factors have been clearly established in the literature: increasing age, African-American ethnicity and family history of PC. 2 None of these risk factors is modifiable. In addition to an aging population, screening with Prostate Specific Antigen (PSA) and increased prostatic procedures have increased diagnosis rates. 3 These trends, along with the aging population and increasing cost of PC treatment, suggest that the burden of PC will continue to escalate and emphasize the need for methods to prevent PC. 4 With no evident modifiable risk factors, the possibility of chemoprevention becomes even more important. Randomized controlled trials show that the 5-alpha-reductase inhibitors finasteride and dutasteride reduce the overall risk of developing PC, but may increase the risk of aggressive or advanced PC. [5] [6] [7] This risk, along with concerns about side effects and cost effectiveness, has curtailed prescription of these drugs for chemoprevention of PC.
Laboratory research suggests that statins may help prevent the development of PC through inhibition of sustained proliferative signals (androgen and Ras/Rho), sensitizing potentially malignant cells to programmed cell death signals, minimizing inflammation, reducing angiogenesis and impeding invasiveness by blocking adhesion molecules. [8] [9] [10] [11] [12] [13] Interfering with these five hallmarks of cancer provides a strong biological rationale for testing the chemopreventive potential of statins.
analysis suggested that exposure to statins may reduce the risk of PC by 7%, but there was substantial heterogeneity. 15 The discrepancies between these studies may reflect their limitations. Most were limited by exposure data confined to the recent past, limited information on dose, timing and duration of statin use, and by the possibility of uncontrolled detection and recall biases. Very few studies have allowed for the long latency of any potential protective effects; the follow-up periods of most studies may have been too short to detect an impact. 16 We aimed to determine if statin use reduces the risk of PC through a nested case-control study with long-term prediagnosis prescription drug data. We also evaluated the effect of statin dose, duration of use and lipophilicity on statin impact on PC risk.
Methods

Study design
A nested case-control study was performed using health care data from Saskatchewan.
Sources of data
Data were obtained from Saskatchewan's health services databases and the Saskatchewan Cancer Registry (SCR). Saskatchewan Health provides publicly funded health care programs, including hospital and physician services, prescription drugs, and cancer therapy, to the 1.1 million residents of the Canadian province. Coverage is universal; there is no eligibility distinction based on age or income. 17 A unique health services number assigned to all residents enables linkage longitudinally and across databases. Because of the availability of long drug use histories, these databases have been used extensively in pharmacoepidemiologic research. 18, 19 The Saskatchewan Prescription Drug Plan (SPDP), in operation since 1975, pays for prescription drugs for all residents, except for Registered Indians and RCMP and military personnel whose prescription drug benefits are fully covered by the federal government. 17 The SPDP database captures data from pharmacy claims for formulary drugs dispensed to eligible beneficiaries and accuracy of the prescription information exceeds 99%. 20 Reporting of cancer cases to SCR is mandated by provincial regulations. 21 Almost all cases are pathologically confirmed (96%), <3% of registrations originate from death certificates, 22 and loss to follow-up is <3%.
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Services provided by hospitals and physicians in Saskatchewan are recorded by the Hospital Services and Medical Services databases. The data collected comprise demographic as well as diagnostic and treatment information including primary diagnosis, coded using the International Classification of Diseases, Ninth Revision (ICD-9) or the ICD-10-CA 24 (after April 2002) 17 and service or procedure codes. Data extraction for this study from the various databases was carried out by employees of the SCR and Saskatchewan Health. To protect participant privacy, the data delivered for analyses did not include any identifying information and none of the subjects were contacted or interviewed.
Source population
The source population consisted of all men aged 40 years or older registered with the SPDP 1990-2010, with no prior history of cancer (except for nonmelanoma skin cancer). Men entered the source population on January 1, 1990 (statin use was very rare before 1990 25 ), their 40th birthday (PC is very rare under 40), or on the date of immigration to Saskatchewan, whichever occurred latest. They left the source population on December 31, 2010, on the date of diagnosis of PC, death or emigration, whichever occurred first. Registered Indians and other federal beneficiaries were excluded because information about their drug prescriptions is not consistently captured in the SPDP. 18 
Identification of cases and controls
The case group included all men, diagnosed with primary prostatic carcinoma (ICD-Oncology code 61; behavior code 3) who were registered with the SCR between January 1, 1990 and December 31, 2010. To avoid outcome misclassification, we excluded those diagnosed by death certificate only and restricted the analyses to histologically confirmed cases with the following morphology codes: 8140/3, 8010/3 and 8000/3. Risk set (incidence density) sampling was used to select matched controls from Saskatchewan Health's population registry. 26 For each case, a risk set was constructed from all eligible men in the source population who had the same birth date (61 year) and postal code of residence, were registered with Saskatchewan Health for as long as the case, and who were alive and free of cancer on the date of diagnosis of the matching case (the index date). Four controls were randomly sampled without replacement from each risk set. To ensure that the histories of exposure, if any, were of adequate length, we only included men for risk-set sampling (both cases and controls) who were eligible to benefit from the SPDP for 5 or more years before the index date.
Comorbidity and screening
The matched design of the nested case-control study controlled for confounding by age, calendar time, place of residence and duration of registration with Saskatchewan Health.
We assessed for potential confounding by indication of statin use (coronary heart disease, and associated conditions such as diabetes and stroke). Previously validated algorithms, based on the frequency of certain ICD codes, were used to identify these conditions from the administrative databases (Table 1) . 27, 28 As frequent interactions with family physicians may be associated with the use of prescribed statins and with the diagnosis of PC, we included this variable to help control for potential confounding by detection bias. Frequency of medical care up to 10 years before diagnosis was assessed with billing codes for visits and services provided by physicians, which are recorded by the Saskatchewan Medical Services Plan (Table 1) . Because we lacked data on PSA testing, we also used these service codes to construct a composite binary variable to help account for likelihood of PSA screening. The screening variable included any physician visit for benign prostatic hyperplasia (BPH), prostatitis, other prostate disorders, and prostatic ablation, resection, or testing of prostatic secretions (Table 1) . We also included variables accounting for visits to a urologist 1-11 years prior to the index date.
Exposure assessment
Detailed histories of use of prescribed statins (Table 1) and 18 other drug classes were obtained from the SPDP for the period between the index date and January 1, 1976, or the coverage initiation date, whichever was later. For each prescription, we had the following information: the date of dispensing, the active ingredient name and strength (mg/pill), and the form and quantity dispensed. Obtained drug classes (Table 1) were intended to cover the full spectrum of prescription drugs, thereby allowing flexibility in adjusting for emerging evidence of effects while awaiting data availability. Based on pre-existing studies, drugs used to treat BPH, diabetes, hypertension and NSAIDs were of particular interest.
Statistical analysis
In the primary analysis, we used conditional logistic regression to model use of statins as a class rather than by individual drugs and repeated the analyses separately for groups of statins defined by lipophilicity.
We excluded the one-year period preceding the index date because drug use shortly before diagnosis could be triggered by symptoms (protopathic bias). 29 After excluding the year prior, we divided the remaining time preceding the index date into successive periods of years: 0-0.5, 0.6-1, 1.1-5, 5.1-10, 10.1-15, 15.1 or more. We then used these periods to analyze the effect of duration of statin use because any potential effects of statins on carcinogenesis are likely to involve a considerable latency period. 30 While statins are not likely to be prescribed for PC symptoms, they can be prescribed as part of a physician visit associated with symptoms.
Exposure during each period was characterized as the average rate of dispensing statins as a class. The rate of dispensing statins was based on the proportion of the defined daily dose (DDD) of each different statin dispensed (p i 5 average mg/day dispensed 4 DDD for statin i ) during each period to account for differences in drug potency within the statin class. The DDD is "the assumed average maintenance dose per day for a drug used for its main indication in adults." 31, 32 The sum of these proportions, that is, Rp i for all the different statins (indexed by "i") dispensed during a period, represented the measure of exposure.
We used conditional logistic regression to estimate incidence density ratios (rate ratios) for the effects of drug exposure during each of the study's time periods while adjusting for the potential confounders. Within each period, statin use was represented by categorical indicator variables indicating quartiles of Rp i . These variables were jointly entered into the model to adjust for mutual confounding by exposure in other periods. 33, 34 We assessed for monotonic linear dose-response (and duration-response) relationships between the quintiles of the average annual dose and PC risk, and used the Mantle extension test 35 and its multivariate counterpart (a v 2 d test for ordered categorical variables in the regression analyses 36 ) to assess the statistical significance of any trends.
We then limited our data set to PC cases in years where we had PSA test information (excluded 2003-2007 and 2010) and used simple logistic regression to evaluate the association between each screening variable and the diagnosis of clinically significant disease. We defined clinically significant disease as: Gleason score 8-10 OR lymph nodes positive for metastatic PC OR clinical stage Whitmore-Jewett C-D OR clinical stage AJCC 3-4.
Results
Between 1990 and 2010, 12,745 cases of prostate cancer were diagnosed in Saskatchewan and these cases were matched on age, index date and geographic location to 50,979 controls. Most cases and controls (74.3%) were 65 years or older (Table 2) . Over 94% of cases were pathologically confirmed and 12.6% had metastatic disease at diagnosis (Table 2) . Between 1990 and 2009, the median age of cases decreased from 75 to 68 years old and the proportion of patients diagnosed with clinically significant disease declined from 40.7 to 30.6%, demonstrating the impact of screening over time (Supporting Information). There were 3,513 individuals diagnosed with clinically significant PC.
Overall, 2,064 (16.2%) cases and 7,956 (15.6%) controls filled at least one statin prescription (Table 3) . Ignoring matching, there were no significant differences in mean or median dose received, as defined by the average annual dose. There were also no significant differences in exposure to 5-alpha-reductase inhibitors and aspirin between cases and controls. In addition to these drugs exposures to prescribed fibrates, other lipid modifying agents, alpha-1-adrenergic receptor blockers and non-aspirin NSAIDs, as well as dose distribution are outlined in Table 3 .
In models accounting for matching, but not adjusting for other confounders, ever filling a prescription for a statin was not associated with risk of PC (odds ratio [OR] 5 1.05, 95% CI 0.99-1.11). Factors associated with PSA screening were associated with an increased risk of PC diagnosis and a decreased risk of clinically significant PC (Table 4) . Specifically, accounting for matching but no other confounders, positivity of the composite screening variable was associated with a dramatically increased risk of PC diagnosis (OR 32.79,95% CI 30.27-35.52) and a noticeable reduction in clinically significant disease (OR 0.77, 95% CI 0.67-0.89).
Multivariable modeling demonstrated no statistically significant relationship between ever prescription of statins (OR (Table 6) . Finally, using multivariable unconditional logistic regression, we found that statin use decreased the risk of clinically significant PC (OR 0.84, 95% CI 0.73-0.97). We used the same variables found to be important in controlling for confounders in the conditional model, but few were as impactful in adjusting for an effect on clinically significant disease. Similar to the evaluation of overall PC, we did not see a linear or consistent significant relationship with either dose or duration of statin use (Table 6 ).
Discussion
Our analysis demonstrated no significant effect of statin use on overall PC diagnosis. Specifically, there was no significant impact on PC diagnosis with statin use regardless of dose or duration of exposure and no matter which statin was prescribed. However, statin use was associated with decreased likelihood of clinically significant PC.
The previous epidemiologic literature examining the effect of statin use on overall PC diagnosis has been highly variable. We previously performed a systematic review demonstrating that risk ratios estimating the effect of statin use on risk of show an increased risk of PC with statin use, 10 demonstrate a decreased risk, and 17 suggest no effect. 37 This level of variation obscures any potential impact of statin use. Ideally, meta-analysis would clarify, but the difficulty in interpreting these studies is that there is high heterogeneity and almost all of them have small sample sizes, significant potential for confounding and recall and selection biases. Many were also handicapped by short-term data on drug exposure, short follow-up or no adjustment for screening.
Examining the two largest cohorts, with the best power to detect an effect of statin use, Murtola et al. showed a 7% (0-16%) increase in risk and Jespersen et al. showed a 6% (3-9%) decrease in risk. Neither estimate was adjusted for screening, health utilization or important prescription drugs such as 5-alpha-reductase inhibitors. 38, 39 After adjusting indirectly for screening and directly for health utilization, comorbidities and other prescription medications, our model showed no impact of statin prescription on PC diagnosis. This suggests that these variables likely do not substantially confound the results. However, the adjustment for PC screening was indirect.
Similar to both the above reports, duration of exposure and dosage did not modify the effect of statin use in our study. A meta-analysis of 15 retrospective studies that reported statin exposure for 5 years or more also reported no impact on overall PC diagnosis: risk ratio 0.89, 95% CI: 0.66-1.12). However, they also reported a reduction in risk of advanced PC: risk ratio 0.87, 95% CI: 0.79-0.95). 16 The very long duration of our prediagnosis drug exposure data suggests that data examining even longer durations of statin use are unlikely to change these trends.
Data on statin use from the two randomized controlled trials (REDUCE and PCPT) investigating the impact of 5-alpha-reductase inhibitors on PC diagnosis represent to date the most consistent approach to PC diagnosis and screening. 40, 41 Evaluation of statin use in the cohorts from these studies suggested no effect of statin use, though both studies had short prediagnosis drug exposure histories based on patient recall. Interestingly, these trials did demonstrate an 25% reduction in rate of PC diagnosis with exposure to dutasteride or finasteride and our data show a similar 27% risk ratio reduction with exposure to 5-alpha-reductase inhibitors.
Despite the strong preclinical rationale, the methodologically most robust epidemiological studies detailed above do not support an effect of statin use on overall PC diagnosis. However, the existing literature and our results suggest that statin use may decrease the risk of clinically significant PC. 15, 42 Specifically, our odds ratio 0.84, is in line with previous meta-analyses. 15, 16 Why might statin use impact development of more aggressive disease, but not PC overall? One possibility is that our understanding of the biological mechanisms of prostate carcinogenesis is incomplete and that the mechanisms inhibited by statins are more important for the development of more aggressive disease. 43 Currently, there is great debate about which epigenetic or genetic events can initiate prostate carcinogenesis, providing at least one clear example of our incomplete understanding. 44 In one recent review, 21 studies reported the effect of statin use on both overall and advanced PC, with 8 showing a statistically significant decrease in advanced PC. 42 Out of these eight, three showed no impact of statin use on overall PC. 39, 45, 46 A systematic review reported an inverse association between statin use and advanced PC (risk ratio 0.87, 95% CI 0.82-0.91) in 11 studies. 16 Given the lack of difference in overall PC diagnosis, this disparity suggests either that statins interfere in tumor progression to more clinically significant disease or that increased PSA screening in statin users with higher healthcare utilization than controls leads to earlier diagnosis. Since PSA screening does not appear to change mortality and most known risk factors have been controlled in our analysis, we would argue the former. 47 However, our adjustment for PC screening was indirect and incomplete adjustment for confounding by PC screening could both mask a benefit of statins in overall PC diagnosis, while simultaneously appearing to reduce the risk of clinically significant disease. The only ways to fully adjust for PC screening would include a randomized controlled trial or an epidemiological study similar to ours with the data necessary to adjust directly for screening.
The strengths of our study include that we used a large cohort of PC cases to assess the impact of statin use on PC diagnosis and used a nested case-control methodology to help decrease confounding. Our cohort also had the longest and most comprehensive prediagnosis drug exposure data and 151 years of follow-up data in >90% of patients. We also believe we are the first to report on a subset of individuals with 151 years of statin use. We attempted to account for many of the limitations in previous studies by linking Saskatchewan data sets, eliminating recall bias, specifying dose and timing of exposure, providing a long lead time on exposure data, and ensuring PC cases were not missed. These characteristics combine to make it methodologically one of the strongest epidemiological assessments of the effect of statin use on PC incidence.
However, our study also has limitations. First, PC screening was indirectly adjusted for using a composite variable constructed to predict PSA testing. While we used components previously associated with PSA testing in the literature, 48, 49 this indirect approach may not entirely adjust for confounding due to differential PSA screening between those prescribed statins and those not prescribed statins. Increased screening in the statin group could mask a beneficial effect of statins, though we did not see such masking with 5-alphareductase inhibitors and increased screening can be counterbalanced by the healthy user effect arising from more health conscious individuals taking preventative medications. 50 However, this remains the most important limitation of our study since the rate of PSA testing rose dramatically in Saskatchewan after the test became available in 1990 and there was a substantial associated increase in PC diagnosis. 23 As an observational study, residual confounding is possible due to unmeasured variables such as ethnicity, physical activity, body mass index, smoking status, cholesterol levels or diet. 51 The known risk factors for PC, ethnicity and family history were not included, but the older non-Aboriginal population of Saskatchewan is quite stable and fairly homogeneous (most Aboriginal men are excluded by design, and <1% of the population in Saskatchewan is of African ancestry 52 ) and there is no reason to believe that family history of PC would differ by statin use.
Conclusion
We found that statin use is not associated with either a protective or detrimental effect on overall PC diagnosis, regardless of duration or dose of exposure. However, statin use may reduce the likelihood of clinically significant PC. This result can provide reassurance to the millions who use these medications on a regular basis. Despite a positive preclinical rationale and some evidence of prevention of clinically significant PC, we believe further studies with both long prediagnosis drug histories and an ability to adjust directly for PC screening are needed before considering embarking on randomized chemoprevention trials.
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